These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10438178)

  • 1. Clozapine-olanzapine: a potentially dangerous switch. A report of two cases.
    Delassus-Guenault N; Jegouzo A; Odou P; Seguret T; Zangerlin H; Vignole E; Robert H
    J Clin Pharm Ther; 1999 Jun; 24(3):191-5. PubMed ID: 10438178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine.
    Chengappa KN; Pollock BG; Parepally H; Levine J; Kirshner MA; Brar JS; Zoretich RA
    J Clin Psychopharmacol; 2000 Jun; 20(3):311-6. PubMed ID: 10831017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching clozapine responders to olanzapine.
    Littrell KH; Johnson CG; Hilligoss NM; Peabody CD; Littrell SH
    J Clin Psychiatry; 2000 Dec; 61(12):912-5. PubMed ID: 11206595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.
    Meltzer HY; McGurk SR
    Schizophr Bull; 1999; 25(2):233-55. PubMed ID: 10416729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine for treatment-refractory psychosis in patients responsive to, but intolerant of, clozapine.
    Weiss EL; Longhurst JG; Bowers MB; Mazure CM
    J Clin Psychopharmacol; 1999 Aug; 19(4):378-80. PubMed ID: 10440469
    [No Abstract]   [Full Text] [Related]  

  • 6. Olanzapine-induced manic-like syndrome.
    Lindenmayer JP; Klebanov R
    J Clin Psychiatry; 1998 Jun; 59(6):318-9. PubMed ID: 9671347
    [No Abstract]   [Full Text] [Related]  

  • 7. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
    Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
    J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series.
    Ahmed S; Chengappa KN; Naidu VR; Baker RW; Parepally H; Schooler NR
    J Clin Psychiatry; 1998 Sep; 59(9):472-7. PubMed ID: 9771818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
    Carlson CD; Cavazzoni PA; Berg PH; Wei H; Beasley CM; Kane JM
    J Clin Psychiatry; 2003 Aug; 64(8):898-906. PubMed ID: 12927004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response.
    Henderson DC; Nasrallah RA; Goff DC
    J Clin Psychiatry; 1998 Nov; 59(11):585-8. PubMed ID: 9862604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine: safe during clozapine-induced agranulocytosis.
    Oyewumi LK; Al-Semaan Y
    J Clin Psychopharmacol; 2000 Apr; 20(2):279-81. PubMed ID: 10770478
    [No Abstract]   [Full Text] [Related]  

  • 16. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal.
    Shiovitz TM; Welke TL; Tigel PD; Anand R; Hartman RD; Sramek JJ; Kurtz NM; Cutler NR
    Schizophr Bull; 1996; 22(4):591-5. PubMed ID: 8938913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of risperidone and olanzapine on the indications for clozapine.
    Ganguli R; Brar JS
    Psychopharmacol Bull; 1998; 34(1):83-7. PubMed ID: 9564203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group.
    Tollefson GD; Dellva MA; Mattler CA; Kane JM; Wirshing DA; Kinon BJ
    J Clin Psychopharmacol; 1999 Oct; 19(5):435-43. PubMed ID: 10505585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine augmentation of clozapine.
    Gupta S; Sonnenberg SJ; Frank B
    Ann Clin Psychiatry; 1998 Sep; 10(3):113-5. PubMed ID: 9781474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.
    Tollefson GD; Birkett MA; Kiesler GM; Wood AJ;
    Biol Psychiatry; 2001 Jan; 49(1):52-63. PubMed ID: 11163780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.